Marycruz Olvera-Valdez

Dr. Marycruz Olvera-Valdez

Instituto Politécnico Nacional, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MRMartha Cecilia Rosales-hernendez
Martha Cecilia Rosales-hernendez
LFLeticia Fragoso
Leticia Fragoso
CJCORREA BASURTO JOSE
CORREA BASURTO JOSE
MOMarycruz Olvera-Valdez
Marycruz Olvera-Valdez
EBEfrén Venancio García Báez
Efrén Venancio García Báez
ACAlejandro ------------------- Cruz
Alejandro ------------------- Cruz
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder. Inhibiting acetylcholinesterase (AChE), amyloid beta (Aβ1-42) aggregation and avoiding the oxidative stress could prevent the progression of AD. Benzothiazole groups have shown neuroprotective activity whereas isothioureas groups act as AChE inhibitors and antioxidants. Therefore, 22 benzothiazole-isothiourea derivatives (3a–v) were evaluated by docking simulations as inhibitors of AChE and Aβ1-42 aggregation. In silico studies showed that 3f, 3r and 3t had a delta G (ΔG) value better than curcumin and galantamine on Aβ1-42 and AChE, respectively. The physicochemical and pharmacokinetics predictions showed that only 3t does not violate Lipinski’s rule of five, though it has moderated cytotoxicity activity. Then, 3f, 3r and 3t were synthetized and chemically characterized for their in vitro evaluation including their antioxidant activity and their cytotoxicity in PC12 cells. 3r was able to inhibit AChE, avoid Aβ1-42 aggregation and exhibit antioxidant activity; nevertheless, it showed cytotoxic against PC12 cells. Compound 3t showed the best anti-Aβ1-42 aggregation and inhibitory AChE activity and, despite that predictor, showed that it could be cytotoxic; in vitro with PC12 cell was negative. Therefore, 3t could be employed as a scaffold to develop new molecules with multitarget activity for AD and, due to physicochemical and pharmacokinetics predictions, it could be administered in vivo using liposomes due to is not able to cross the BBB.

9 October 2024 in Molecules
Verified
Journal Article
Open access
PDF file
MRMartha Cecilia Rosales-hernendez
Martha Cecilia Rosales-hernendez
MOMarycruz Olvera-Valdez
Marycruz Olvera-Valdez
JVJazziel Velazquez
Jazziel Velazquez
JMJessica Elena Mendieta-Wejebe
Jessica Elena Mendieta-Wejebe
LFLeticia Fragoso
Leticia Fragoso
ACAlejandro ------------------- Cruz
Alejandro ------------------- Cruz
Despite the great effort that has gone into developing new molecules as multitarget compounds to treat Alzheimer’s disease (AD), none of these have been approved to treat this disease. Therefore, it will be interesting to determine whether benzazoles such as benzimidazole, benzoxazole, and benzothiazole, employed as pharmacophores, could act as multitarget drugs. AD is a multifactorial disease in which several pharmacological targets have been identified—some are involved with amyloid beta (Aβ) production, such as beta secretase (BACE1) and beta amyloid aggregation, while others are involved with the cholinergic system as acetylcholinesterase (AChE) and butirylcholinesterase (BChE) and nicotinic and muscarinic receptors, as well as the hyperphosphorylation of microtubule-associated protein (tau). In this review, we describe the in silico and in vitro evaluation of benzazoles on three important targets in AD: AChE, BACE1, and Aβ. Benzothiazoles and benzimidazoles could be the best benzazoles to act as multitarget drugs for AD because they have been widely evaluated as AChE inhibitors, forming π–π interactions with W286, W86, Y72, and F338, as well as in the AChE gorge and catalytic site. In addition, the sulfur atom from benzothiazol interacts with S286 and the aromatic ring from W84, with these compounds having an IC50 value in the μM range. Also, benzimidazoles and benzothiazoles can inhibit Aβ aggregation. However, even though benzazoles have not been widely evaluated on BACE1, benzimidazoles evaluated in vitro showed an IC50 value in the nM range. Therefore, important chemical modifications could be considered to improve multitarget benzazoles’ activity, such as substitutions in the aromatic ring with electron withdrawal at position five, or a linker 3 or 4 carbons in length, which would allow for better interaction with targets.

17 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MOMarycruz Olvera-Valdez
Marycruz Olvera-Valdez
EMElmer Joel Millan-Casarrubias
Elmer Joel Millan-Casarrubias
HBHector Barrios-Piña
Hector Barrios-Piña
Freshwater pesticide contamination represents an important environmental and public health concern in regions with intensive agricultural activity. Lake Chapala, the largest freshwater reservoir in Mexico, contains multiple pesticide residues, while nearby populations present high prevalence of chronic renal and systemic diseases. In this study, an in silico environmental toxicology approach integrating physicochemical characterization, ADMET prediction, and molecular docking was employed to evaluate the potential interaction of detected pesticides with proteins associated with renal, hepatic, neurological, inflammatory, and metabolic disorders, including AChE, CA II, GSK3β, IDO1, MAOB, and EGFR. The results showed that hydrophilic compounds such as glyphosate and AMPA may favor continuous systemic exposure through contaminated water, however organochlorines exhibited greater lipophilicity and bioaccumulation potential. Atrazine metabolites and DDT/DDD derivatives displayed the strongest binding affinities toward proteins involved in oxidative stress, neuronal signaling, renal physiology, and inflammatory pathways. These findings suggest that chronic exposure to freshwater contaminants may contribute to multisystemic disease development through complementary molecular mechanisms. Overall, this study provides mechanistic evidence linking pesticide contamination in Lake Chapala with molecular pathways associated with chronic renal, hepatic, and neurodegenerative diseases.